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Pulmonary fibrosis is a progressive and irreversible fibrotic lung disorder with high
mortality and few treatment options. Recently, induced pluripotent stem (iPS) cells have
been considered as an ideal resource for stem cell-based therapy. Although, an earlier
study demonstrated the therapeutic effect of iPS cells on pulmonary fibrosis, the exact
mechanisms remain obscure. The present study investigated the effects of iPS cells
on inflammatory responses, transforming growth factor (TGF)-β1 signaling pathway,
and epithelial to mesenchymal transition (EMT) during bleomycin (BLM)-induced lung
fibrosis. A single intratracheal instillation of BLM (5 mg/kg) was performed to induce
pulmonary fibrosis in C57BL/6 mice. Then, iPS cells (c-Myc-free) were administrated
intravenously at 24 h following BLM instillation. Three weeks after BLM administration,
pulmonary fibrosis was evaluated. As expected, treatment with iPS cells significantly
limited the pathological changes, edema, and collagen deposition in lung tissues
of BLM-induced mice. Mechanically, treatment with iPS cells obviously repressed
the expression ratios of matrix metalloproteinase-2 (MMP-2) to its tissue inhibitor -
2 (TIMP-2) and MMP-9/TIMP-1 in BLM-induced pulmonary tissues. In addition, iPS
cell administration remarkably suppressed BLM-induced up-regulation of pulmonary
inflammatory mediators, including tumor necrosis factor-α, interleukin (IL)-1β, IL-6,
inducible nitric oxide synthase, nitric oxide, cyclooxygenase-2 and prostaglandin E2. We
further demonstrated that transplantation of iPS cells markedly inhibited BLM-mediated
activation of TGF-β1/Mothers against decapentaplegic homolog 2/3 (Smad2/3) and
EMT in lung tissues through up-regulating epithelial marker E-cadherin and down-
regulating mesenchymal markers including fibronectin, vimentin and α-smooth muscle
actin. Moreover, in vitro, iPS cell-conditioned medium (iPSC-CM) profoundly inhibited
TGF-β1-induced EMT signaling pathway in mouse alveolar epithelial type II cells
(AECII). Collectively, our results suggest that transplantation of iPS cells could suppress
inflammatory responses, TGF-β1/Smad2/3 pathway and EMT during the progression of
BLM-induced pulmonary fibrosis, providing new useful clues regarding the mechanisms
of iPS cells in the treatment for this disease.
Keywords: bleomycin, epithelial to mesenchymal transition (EMT), induced pluripotent stem (iPS) cells,
inflammation, pulmonary fibrosis, TGF-β1
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INTRODUCTION
Pulmonary fibrosis is a chronic interstitial lung disease, which
is characterized by inflammatory injury of alveolar epithelial
cells, excessive proliferation of fibroblasts, aberrant deposition of
extracellular matrix (EMC), and abnormal repair and remodeling
of lung tissue (White et al., 2003). These pathologic changes
result in progressive decline in pulmonary function, eventually
leading to respiratory failure (Wynn, 2011). Previous studies
have suggested that pulmonary inflammation is an early event
during the development of pulmonary fibrosis, as evidence
by the release of various inflammatory mediators (Kandhare
et al., 2015). Anti-inflammation agents like cytokines antagonists,
nuclear factor (NF)-κB antagonists and inducible nitric oxide
synthase (iNOS) inhibitors have been proposed as treatment
option for lung fibrosis (Woodcock and Maher, 2014). Emerging
evidence indicates that epithelial to mesenchymal transition
(EMT) has a critical role in the progression of fibrotic lung
diseases due to its contribution to the generation of numerous
ECM-producing fibroblasts/myofibroblasts (Andersson-Sjoland
et al., 2008; Omenetti et al., 2008). Transforming growth factor
(TGF)-β1/Smad2/3 signaling is one of the main pathways
involved in a variety of pulmonary fibrogenesis processes,
including inflammation, EMT, and ECM deposition. In the
past few years, TGF-β1 pathway has attracted considerable
attention from researchers as a therapeutic target for lung fibrosis
(D’Alessandro-Gabazza et al., 2012; Dong et al., 2012). However,
although various potential therapeutics for pulmonary fibrosis
have been widely applied in clinical trials, this disease still has
a high mortality rate of up to 40% within 5 years of diagnosis
(Antoniou et al., 2013; Gomer, 2013). Therefore, exploring new
effective strategies for ameliorating pulmonary fibrosis is a top
priority.
Stem cell-based approaches, including the use of mesenchymal
stem cells (MSCs) or embryonic stem (ES) cells, have been
widely studied for their effects in treating pulmonary fibrosis
(Ortiz et al., 2003; Moodley et al., 2009; Banerjee et al., 2012;
Spitalieri et al., 2012). However, there are some concerns with
regards to the efficiency and availability of MSCs due to their
limited life span when cultured in vitro (Pozzobon et al., 2010).
Additionally, the problems of ethical concerns and immune
rejection following transplant restrict the clinical application of
ES cells. Recently, induced pluripotent stem (iPS) cells, derived
from adult somatic cells via reprogramming by introduction
of specific pluripotency genes, have opened a novel avenue
for stem cell-based therapies (Takahashi et al., 2007). iPS cells
share the similar characteristics such as morphology, self-renewal
abilities, gene expression, and surface antigens with ES cells
and avoid the ethical and immunorejective problems. More
importantly, a recent report has found that iPS cells have more
potent immunomodulatory effects compared with bone marrow-
derived MSCs in vitro (Schnabel et al., 2014). Accordingly, iPS
cells could be suggested as quite promising candidates for cell
therapies and regenerative medicine.
In general, introduction of four genes, including Oct4, Sox2,
Klf4 and c-Myc, to somatic cells results in generation of iPS
cells, which can lead to pluripotency comparable with ES cells.
Surprisingly, recent studies have successfully generated 3-gene
iPS cells (c-Myc-free) from fibroblasts, which were shown low
tumorigenic risk (Li et al., 2011; Yang et al., 2011). Notably, How
et al. (2013) demonstrated that 3-gene iPS cell transplantation
could attenuate bleomycin (BLM)-induced pulmonary fibrosis
partially via the early amelioration of inflammation. However,
whether other mechanisms are involved in the therapeutic effects
of specific-iPS cells on lung fibrosis remains uncertain. In the
present study, we hypothesized that iPS cell transplantation could
mitigate TGF-β1/Smad2/3 signaling pathway as well as EMT
process during pulmonary fibrosis. To test the hypothesis, we
developed a BLM-induced pulmonary fibrosis mouse model,
and demonstrated that not only amelioration of pulmonary
inflammation but also inhibition of TGF-β1 signaling and EMT
process were involved in the anti-fibrotic effects of iPS cells.
MATERIALS AND METHODS
Animals
C57BL/6 mice were purchased from Vital River Laboratory
Animal Technology, Co. Ltd (Beijing, China). The mice were
raised under controlled conditions (temperature 22 ± 1◦C and
humidity 40–60%) with 12 h dark/light cycle. All animal care and
experimental protocols were approved by the Animal Care Ethics
and Use Committee of China Medical University and performed
in accordance with the guidelines of this committee.
The Isolation of Mouse Embryonic
Fibroblasts (MEFs)
Mouse embryonic fibroblasts were isolated from 12.5∼14.5-day-
old embryos of female C57BL/6 mice. Briefly, embryos were
separated from the uterus of mice at day 12.5∼14.5 post-
conception, and the viscera and head of each embryo were
removed. Then, the remaining embryos were washed with
phosphate-buffered saline (PBS), minced into small pieces (1–
3 mm3), digested with 0.25% trypsin-EDTA (Sigma-Aldrich, St.
Louis, MO, USA), and incubated in Dulbecco’s Modified Eagle’s
Medium (DMEM; Gibco, MD, USA) supplemented with 10%
fetal bovine serum (FBS; Hyclone, USA) and 1% penicillin-
streptomycin at 37◦C in humidified atmosphere with 5% CO2.
After filtering and centrifuging, the cells were counted and seeded
in 12-well plates for the following experiments.
The Generation of Mouse iPS Cells and
the Culture of ES Cells
Mouse iPS cells were generated from MEFs and reprogrammed
according to previous studies with minor modification (How
et al., 2013). Briefly, MEFs were seeded into 6-well plates and
cultured overnight in fibroblasts medium consisting of DMEM,
10% FBS and 1% penicillin-streptomycin. When reached 70%
confluence, cells were transfected with lentiviral vectors (Hanbio,
Shanghai, China) encoding three transcription factors including
Oct4, Sox2, and Klf4 in the presence of ploybrene (4 µg/ml;
Sigma-Aldrich, St. Louis, MO, USA). After 24 h of infection,
the cells were released in fresh medium. Forty-eight hours
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after transduction, the cells were cultured using mouse iPS cell
medium which consists of DMEM, 15% FBS, 2 mM glutamine,
0.1 mM non-essential amino acids (NEAAs), and 0.1 mM
β-mercaptoethanol, and the medium was changed every other
day. Subsequently, the iPS cells formed clones on MEFs and the
clones were subjected to expansion for other experiments.
Mouse ES cells were purchased from Shanghai Institute
of Cell Resource Center of Life Science (Shanghai, China).
Cells were cultured in DMEM medium supplemented with
15% FBS (Invitrogen, Carlsbad, CA, USA), 1% NEAA, 0.25%
β-mercaptoethanol, and 1% LIF (1000 U/ml; Millipore, MA,
USA) at 37◦C in humidified atmosphere with 5% CO2.
The Preparation of the iPS
Cell-Conditioned Medium (iPSC-CM)
The well-grown iPS cells were seeded into 6-well plates for
24 h, and then cultured with FBS-free DMEM supplemented
with 2 mM glutamine, 0.1 mM NEAAs, and 0.1 mM
β-mercaptoethanol. After 48 h of incubation, the culture medium
were collected and centrifuged at 1500 rpm for 10 min. The
supernatant was obtained to be used as the iPSC-CM in
subsequent in vitro experiments.
The Isolation and Treatment of Mouse
Alveolar Epithelial Type II Cells (AECII)
Primary mouse AECII isolation was conducted as previously
described (Mutze et al., 2015). In brief, the lungs of female
C57BL/6 mice were washed with PBS and inflated with 0.25%
trypsin followed by incubation for 20 min at 37◦C. Subsequently,
the lungs were minced into small pieces, filtered through 100 and
60 µm stainless meshes, and the cell suspension was centrifuged
at 1000 rpm at 4◦C for 10 min. After re-suspension in DMEM,
the cells underwent percoll gradient centrifugation (10 and 30%)
at 1000 rpm at 4◦C for 20 min. Thereafter, the cells in 10%
interphase as well as between 10 and 30% interphase were
recovered, re-suspended, and cultured in DMEM containing
10% FBS, 2 mM L-glutamine, 1% penicillin-streptomycin, and
3.6 mg/ml glucose. Following 24 h of incubation, AECII were
treated with the above collected iPSC-CM (100%) and/or TGF-
β1 (5 ng/ml) for 48 h, whereas the control cells were released in
the normal iPS medium.
Reverse Transcription-Polymerase Chain
Reaction (PCR)
Total RNAs from MEFs, iPS cells and ES cells were prepared
by using RNApure Rapid Extraction Kit (BioTeke Corporation,
Beijing, China) according to the instructions of the manufacturer.
Reverse transcription of equal total RNA was performed using
oligo (dT) primer and Super M-MLV reverse transcriptase
(BioTeke Corporation) to generate complementary DNA
(cDNA). Then, cDNA was amplified by using reverse
transcription- polymerase chain reaction (RT-PCR) with
the specific primers and Taq PCR Master-mix (BioTeke
Corporation), which was performed in Life Express PCR
(BIOER, Hangzhou, China). The primer information used is
presented in Table 1. β-actin was used as the internal control
gene. The reverse transcription- PCR conditions were as follows:
(1) an initial incubation at 95◦C for 5 min, (2) denaturation at
95◦C for 20 s, (3) annealing at 54◦C for 20 s, and (4) extension at
72◦C for 30 s. Steps (2–4) were repeated for 35 cycles, followed
by a final polymerization at 25◦C for 5 min. Subsequently, the
PCR amplification products (Oct4, Sox2, Nanog, Klf4, Fbx15,
and β-actin) were visualized in 1.5% agarose gel and analyzed
using Gel Imaging Analyzer (Liuyi, Beijing, China).
BLM-Induced Pulmonary Fibrosis in Mice
Male C57BL/6 mice were randomly divided into three groups,
including the control group (also the sham group), BLM-induced
group (BLM group), and iPS cell treatment group (BLM+iPS
group). All mice were anesthetized by intraperitoneal injection
with 10% chloral hydrate (3.5 ml/kg) followed by separating
trachea from esophagus via blunt dissection. For the induction of
pulmonary fibrosis, mice were then given a single intratracheal
instillation of BLM (5 mg/kg body weight in 0.1 ml sterile
normal saline; Melonepharma, Dalian, China). Meanwhile, the
mice in the sham group received an equal volume of sterile
normal saline by the same pattern. After 24 h of BLM instillation,
the iPS cell treatment group received tail vein injection with
0.5 ml PBS containing 2 × 106 iPS cells, while other mice were
given intravenous injection of equal volume of PBS as control.
On day 21 after BLM instillation, mice from each group were
anesthetized and bronchoalveolar lavage fluid (BALF) collection
was performed by lavaging the lung three times with total
1.5 ml aliquots of normal saline via a tracheal catheter. Following
sacrifice, lung tissues were rapidly excised. Some right lung were
weighted (wet weight), and then dried until a constant weight
(dry weight) was obtained. Some right lungs were fixed in 4%
paraformaldehyde, and some left tissues were kept at −80◦C
for subsequent real time-PCR and Western blot analyses. On
day 0 and day 21, body weight of each mouse was recorded,
respectively.
Histologic Examination
The paraformaldehyde-fixed pulmonary specimens were
dehydrated in gradient ethanol, embedded in paraffin, and
TABLE 1 | Sequences of the primers used for reverse
transcription-polymerase chain reaction.
Gene name Primer sequence (5′–3′) Product size (bp)
Oct4 F: CCCAACGAGAAGAGTATGAGG 177
R: GAGCAGTGACGGGAACAGA
Sox2 F: GCACAGATGCAACCGATGC 167
R: TCGGACTTGACCACAGAGCC
Nanog F: CAGGGCTATCTGGTGAACG 202
R: CGAAGTTATGGAGCGGAGC
Klf4 F: CCTACTTATCTGCCTTGCTGATTGTC 142
R: CCCCCAGATTGCCCGAGAT
Fbx15 F: GGGATAAAGAAGATGGATACTGG 161
R: GATTGTCCAACCTAAGCCAGA
β-actin F: CTGTGCCCATCTACGAGGGCTAT 155
R: TTTGATGTCACGCACGATTTCC
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sliced into sections at 5 µm. After dewaxing and hydration,
the sections were subjected to hematoxylin and eosin (HE)
staining and Masson staining. For HE staining, the sections were
stained with hematoxylin (Solarbio, Beijing, China) for 5 min
and immersed into 1% hydrochloric ethanol. After washing, the
sections were counterstained with eosin for 3 min. For Masson
staining, the sections were stained with hematoxylin for 6 min
and then ponceau acid fuchsin for 1 min. Following treatment
with 1% phosphomolybdic acid for 5 min, the sections were
counterstained with aniline blue solution. Subsequently, all slices
were dehydrated with gradient ethanol, permeabilized in xylene,
mounted with resin, and finally observed under a microscope
(DP73; Olympus, Tokyo, Japan).
Enzyme-Linked Immunosorbent Assay
(ELISA)
The levels of interleukin (IL)-1β, IL-6, tumor necrosis factor
(TNF)-α and TGF-β1 in BALF were determined using respective
commercial Mouse ELISA Kits (Boster, Wuhan, China)
according to the manufactures’ instructions. After the reaction,
the optical density was measured at 450 nm by using a plate
reader (ELX-800, BIOTEK, USA).
The collagen content in the mouse lung tissues was examined
by collagen I (Col I) assay and hydroxyproline (Hyp) assay using
respective commercial Mouse ELISA Kits (Col I kit from USCN,
Wuhan, China; Hyp kit from Nanjing Jiancheng Bioengineering
Company, Nanjing, China). Left lungs were homogenized in
PBS, and the protein concentrations in the supernatants of
homogenate were then determined using BCA Protein Assay
Kit (Wanleibio, Shenyang, China). Subsequently, all steps of
the Col I and Hyp assay were performed according to the
protocols of manufacturers. For Col I assay, the absorbance of
each sample at 450 nm was measured by a plate reader and
the level of lung Col I was expressed as µg/g of wet lung.
For Hyp assay, the samples were determined for absorbance
at 550 nm using a UV752 spectrophotometer (Yoke, Shanghai,
China), and the Hyp content was expressed as µg/mg of
proteins.
The levels of prostaglandin E2 (PGE2) and nitric oxide
(NO), two major inflammatory mediators, were measured in the
supernatants of lung homogenate by using commercial ELISA
Kit (USCN, Wuhan, China) and Griess reagent Kit (Beyotime,
Jiangsu, China), respectively, following the instructions provided
by the manufacturers. For PGE2 assay, the absorbance at 450 nm
was determined using a plate reader and the amounts of
PGE2 were expressed as pg/mg of proteins. For NO assay, the
absorbance of each well was read at 540 nm wavelength, and the
values were expressed as µmol/g of proteins.
Immunohistochemical Staining
For immunohistochemistry, paraffin-embedded pulmonary
sections were deparaffinized with xylene, hydrated in gradient
ethanol, and microwaved for 10 min for antigen retrieval.
After washing with PBS, the sections were incubated with 3%
H2O2 for 15 min to quench the endogenous peroxidase activity
and blocked with goat serum (Solarbio, Beijing, China) for
15 min at room temperature. Subsequently, the sections were
incubated with primary antibodies against iNOS (1:200) and
xyxlooxygenase-2 (COX-2; 1:200) (Boster, Wuhan, China) in a
humidified chamber at 4◦C overnight. After rinsing with PBS,
the slides were incubated with biotinylated goat anti-rabbit
secondary antibody (1:200; Beyotime) for 30 min at 37◦C and
then avidin-biotin- horseradish peroxidase (HRP; Beyotime) for
30 min at 37◦C. Finally, the sections were visualized by adding
diaminobenzidine (DAB), counterstained with hematoxylin, and
examined under light microscope.
Immunofluorescence Staining
Paraffin-embedded lung tissue sections were deparaffinized and
rehydrated with xylene and gradient ethanol, respectively. After
antigen retrieval by microwaving for 10 min, the slides were
blocked with goat serum for 30 min at room temperature,
followed by incubation with primary antibody E-cadherin (1:100;
Boster) in a humidified chamber at 4◦C overnight. Then, tissue
sections were rinsing with PBS and incubated with Cy3-labeled
goat anti-rabbit IgG (1:200; Beyotime) in a humidified chamber
for 1 h at room temperature. Thereafter, nuclear staining was
performed using DAPI (Biosharp, Hefei, China), and tissue
sections were mounted in neutral glycerine and observed under a
fluorescence microscopy (BX53; Olympus, Tokyo, Japan).
Following treatment, the AECII cultured on coverslips were
fixed for 15 min in 4% paraformaldehyde and permeabilized with
0.1% TritonX-100 at room temperature for 30 min. After blocked
with goat serum for 15 min, the slides were incubated with the
primary antibody E-cadherin (1:200; Boster) in a humidified
chamber at 4◦C overnight followed by Cy3-labeled goat anti-
rabbit IgG (1:200; Beyotime) for 60 min at room temperature.
Then, nuclear staining was performed using DAPI. Finally, the
slides were mounted in neutral glycerine and observed under a
fluorescence microscopy.
Quantitative Real Time-PCR
Total RNA was extracted from lung tissues by using RNA
simple Total RNA Kit (TIANGEN Biotech, Beijing, China)
according to the instructions of manufacturer. Equal RNA
was subjected to reverse transcription in a reaction system
containing M-MLV reverse transcriptase and random primers.
Subsequently, quantitative real time PCR was performed using
SYBR green Master Mix (Solarbio) on Exicycler 96 Real-Time
Quantitative Thermal Block (BIONEER, Daejeon, South Korea).
The primers used for quantitative real time PCR are shown in
Table 2. β-actin served as an internal control to normalize the
expression of mRNA. The conditions of PCR were as follows:
an initial incubation at 95◦C for 5 min, followed by 40 cycles of
denaturation at 95◦C for 10 s, annealing at 60◦C for 20 s, and
extension at 72◦C for 30 s, and a final incubation at 4◦C for 5 min.
The relative gene expression analysis was conducted using the
2−11CT method.
Western Blot Analysis
Total protein was extracted from lung tissues or AECII
using Total Protein Extraction Kit (Wanleibio) and protein
concentrations were determined using BCA Protein Assay
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TABLE 2 | Sequences of the primers used for real time-polymerase chain
reaction.
Gene name Primer sequence (5′–3′) Product size (bp)
iNOS F: GCAGGGAATCTTGGAGCGAGTTG 139
R: GTAGGTGAGGGCTTGGCTGAGTG
COX-2 F: GATGACTGCCCAACTCCCA 193
R: TGAACCCAGGTCCTCGCTTA
TGF-β1 F: GCAACAATTCCTGGCGTTACCT 129
R: GAAAGCCCTGTATTCCGTCTCC
E-cadherin F: TCAAAGTGGCGACAGACGG 185
’ R: GTTGGATTCAGAGGCAGGGT
β-actin F: CTGTGCCCATCTACGAGGGCTAT 155
R: TTTGATGTCACGCACGATTTCC
Kit (Wanleibio) according to the respective manufacturers’
protocols. Equal amount of protein (40 µg) was separated
by 8%-14% SDS-PAGE and transferred onto polyvinylidene
fluoride (PVDF) membranes (Millipore). After blocking with
5% non-fat milk or 1% BSA in Tris Buffered Saline with
Tween 20 (TBST) for 1 h at room temperature, the membranes
were incubated overnight at 4◦C with the following primary
antibodies: α-SMA (1:400), iNOS (1:400), COX-2 (1:400),
E-cadherin (1:400), Fibronectin (1:400) (BOSTER, Wuhan,
China), matrix metalloproteinase (MMP)-2 (1:500), MMP-9
(1:500), p-Smad2 (1:500), Smad2 (1:500), p-Smad3 (1:500),
Smad3 (1:500), Vimentin (1:500) (Bioss, Beijing, China), or
tissue inhibitor of metalloproteinases (TIMPs)-1 (1:200), TIMP-2
(1:200), TGF-β1 (1:200) (Santa Cruz, TX, USA). Subsequently,
the blots were washed four times with TBST, followed by
incubation with HRP-conjugated goat anti-rabbit IgGs (1:5000;
Wanleibio) or goat anti-mouse IgGs (1:5000; Beyotime) for
45 min at 37◦C. After washing six times with TBST for 5 min
each, the interest proteins were developed using enhanced
chemiluminescence (ECL; Wanleibio) and the densitometric
analysis was conducted with Gel-Pro-Analyzer system (Liuyi,
Beijing, China). Thereafter, the membranes were stripped and re-
probed with β-actin antibody (1:1000, Santa Cruz), which served
as an internal control.
Statistical Analysis
The results were presented as mean ± standard deviation
(SD) and analyzed using GraphPad Prism Software Version
5.0 (GraphPad Software, Inc., La Jolla, CA, USA). Statistical
differences among different groups were assessed by one-way
analysis of variance (ANOVA) followed by Newman–Keul’s test.
When p < 0.05, the results were considered to indicate statistical
significance.
RESULTS
The Characterization of iPS Cells and
their Effects on BLM-Induced Pulmonary
Histological Damage in Mice
To generate mouse iPS cells, we performed lentiviral transfection
into MEFs with vectors carrying three genes (Oct4, Sox2, and
FIGURE 1 | Characterization of mouse induced pluripotent stem (iPS)
cells. Reverse transcription-PCR was performed to examine the expression
of mouse embryonic stem (ES) cells maker genes in iPS cells, including Oct4,
Sox2, Nanog, Klf4, and Fbx15. β-actin was used as an internal control.
Mouse embryonic fibroblasts (MEFs) were served as the negative control and
ES cells were served as the positive control. M represents marker bands.
Klf4). After 2 or 3 weeks of culture, iPS cell colonies were
detected. The results of reverse transcription-PCR showed that
the iPS cells expressed a gene signature similar to ES cell markers,
including Oct4, Sox2, Nanog, Klf4, and Fbx15 (Figure 1).
Treatment with BLM led to a significant increment in the
lung wet-to-dry weight ratio (W/D) compared with the control
group (Figure 2A). Nevertheless, the increased W/D of the BLM-
induced mice was remarkably reduced by intravenous delivery of
iPS cells 24 h after BLM administration. In addition, compared
to the control group, BLM administration resulted in an obvious
loss of body weight, which was inhibited by the treatment of
iPS cells (Figure 2B). Histologically, the lung alveoli in the sham
group had well-organized hollow cavities with thin lined alveolar
septa (Figure 2C). On the contrary, markedly histological
abnormalities were observed in the lung tissue sections from
BLM model group, as shown by obviously collapsed alveolar
spaces, thickened alveolar walls, and dense interstitial infiltration
by fibroblasts and inflammatory cells. Of interest, the treatment
with iPS cells significantly limited inflammatory infiltration and
thickened alveolar septa induced by BLM instillation.
iPS Cells Inhibit BLM-Induced Collagen
Deposition in Mice
Masson staining was performed to examine collagen fibers
in pulmonary tissues, which were presented in blue. As
shown in Figure 3A, a large quantity of collagen fibers (blue
staining), markedly interstitial fibroplasias, and distorted lung
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FIGURE 2 | Effects of iPS cell transplantation on lung histological damage in mice with bleomycin (BLM)-induced pulmonary fibrosis. All mice except
controls were intratracheally instilled with BLM (5 mg/kg), while the controls were received an equal volume of normal saline by the same pattern (also as the sham
group). In BLM+ iPS group, mice were i.v. injected with iPS cells after 24 h of BLM instillation. Lung tissues were collected on day 21 after BLM treatment. (A) Some
right lung lobes were weighted and then dried to obtain a constant weight. The lung wet-to-dry weight ratio was calculated. (B) The body weight of each mouse was
recorded on day 0 and day 21, respectively. (C) Lung tissue sections from control mice, BLM-induced mice and BLM+iPS mice were stained with Hematoxylin and
eosin for histological assessment, and the representative images are shown. Original magnification was 200×. Data are expressed as mean ± SD (n = 6).
∗∗p < 0.01 vs. the control group; ##p < 0.01 vs. the BLM group.
morphologies were observed in the lungs from BLM-induced
mice compared with the sham mice. In addition, we also assessed
the contents of Col I and Hyp in lung tissues of mice, which
are considered as fibrotic markers. Compared with the sham
group, the lung Col I and Hyp levels were both drastically
increased in the BLM model group (Figures 3B,C). These data
indicated that the pulmonary fibrosis model induced by BLM
was successfully established. As expected, iPS cell treatment
significantly suppressed the formation of collagen fibers as well
as the up-regulation of Col I and Hyp induced by BLM.
It has been described that during the process of fibrosis,
MMP-2 and MMP-9 respectively called gelatinase A and
gelatinase B are usually up-regulated, which can disrupt
basement membranes through degrading Collagen type IV and
induce lung tissue remodeling as well as alveolar thickening,
resulting in lung fibrosis (Dancer et al., 2011; Van Doren,
2015). Here, the expression levels of MMP-2, MMP-9 and
their corresponding tissue inhibitors (TIMP-2 and TIMP-
1) were evaluated by Western blot analysis. As indicated
in Figure 3D, the expression of MMP-2 and MMP-9 was
significantly up-regulated in BLM-treated mice compared
with the control mice, whereas the expression of TIMP-
2 and TIMP-1 was obviously down-regulated. As expected,
treating with iPS cells remarkably inhibited BLM-mediated
imbalance in the expression ratios of MMP-2/TIMP-2 and MMP-
9/TIMP-1.
iPS Cells Suppress the Lung
Inflammatory Response in BLM-Induced
Mice
It is well-known that inflammation plays a critical role in
the pathogenesis of pulmonary fibrosis. We also observed
decreased inflammatory cell infiltration in BLM-induced lung
tissues as a result of treatment with iPS cells, the potential
mechanisms involved in such anti-inflammatory effect were
therefore investigated. As shown in Figures 4A–C, a significant
increase in the levels of TNF-α, IL-1β and IL-6, several pro-
inflammatory cytokines, was observed in the BALF of BLM-
induced mice compared with the sham control group. Of
note, iPS cell treatment obviously repressed BLM-induced up-
regulation of these cytokines in the BALF.
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FIGURE 3 | Effects of iPS cell treatment on BLM-induced collagen deposition in mice. (A) Pulmonary tissue sections from each group were subjected to
Masson’s staining for the visualization of collagen deposition. The representative images are shown. Original magnification was 200×. (B,C) Collagen I expression
(B) and hydroxyproline content (C) in mouse lung tissues from each group were determined using ELISA kits. (D) The protein expression levels of MMP-2, MMP-9,
TIMP-1, and TIMP-2 in lung tissues from each group were determined using Western blot analysis. The representative bands are shown (left), and the relative band
intensity ratios of MMP-2/TIMP-2 and MMP-9/TIMP-1 were analyzed (right). Data are presented as mean ± SD (n = 6). ∗∗p < 0.01 vs. the control group; ##p < 0.01
vs. the BLM group.
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FIGURE 4 | Effects of iPS cells on the levels of inflammatory cytokines and mediators in BLM-induced pulmonary fibrosis mice. (A–C) The levels of
TNF-α (A), IL-1β (B) and IL-6 (C) in BALF of each mouse from control group, BLM-induced group, and BLM+iPS group were detected by ELISA kits. (D,E) The NO
level (D) and PGE2 content (E) in mouse lung tissues from each group were also determined using ELISA kits. Results are expressed as mean ± SD (n = 6).
∗∗p < 0.01 vs. the control group; ##p < 0.01 vs. the BLM group.
Considering evidence that overproduction of NO has an
essential role for the lung inflammatory response during the
development of pulmonary fibrosis (Liu et al., 2012), the level of
NO production was detected in the lung tissue samples. As shown
in Figure 4D, in contrast to the mice in the sham control group,
BLM instillation caused a remarkable elevation of NO level in the
pulmonary tissues, while such rise was significantly inhibited by
treatment with iPS cells. Furthermore, to investigate whether the
inhibition of NO production was via suppressing the expression
of iNOS, an enzyme that synthesizes NO, iNOS mRNA and
protein levels were determined by quantitative real-time PCR
as well as Western blot and immunohistochemical analyses,
respectively. Consistent with its repression of NO production,
iPS cell treatment significantly inhibited BLM-induced up-
regulation of iNOS expression at both mRNA and protein levels
(Figures 5A–C).
PGE2, an important inflammatory mediator, is produced
from arachidonic acid mainly by COX-2. Several studies have
reported that COX-2-induced PGE2 has also been linked to
the pathogenesis of pulmonary fibrosis (Stratton and Shiwen,
2010; Zhao et al., 2014). The ELISA results indicated that the
PGE2 level of lung tissues significantly increased in BLM-induced
mice compared with the mice in the sham group, but markedly
decreased by the following iPS cells treatment (Figure 4E).
Additionally, data from real time PCR, immunohistochemistry
and Western blot analyses revealed that the expression level
of COX-2 paralleled that of PGE2 in the lung tissues of mice
(Figures 5A–C). Taken together, these findings indicated that
iPS cell treatment could protect the lung against BLM-induced
deleterious inflammation.
iPS Cells Inhibit TGF-β/Smad2/3
Signaling Activated by BLM in Mice
TGF-β1, a potent profibrotic factor, plays a pivotal role
throughout the whole process of pulmonary fibrosis, including
lung inflammatory response, fibroblasts proliferation,
transformation of fibroblasts to myofibroblasts, and EMT.
This study investigated whether TGF-β signaling was involved
in the antifibrotic effects of iPS cells. The ELISA results showed
that BLM induced a significant increase in TGF-β1 level of
BALF which was obviously inhibited after iPS cell treatment
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FIGURE 5 | Effects of iPS cells on the expression of iNOS and COX-2 in lung tissues of BLM-induced mice. (A) The mRNA expression levels of iNOS and
COX-2 in pulmonary tissues from each group were measured using real time PCR. (B) The protein expression levels of iNOS and COX-2 in lung tissue specimens
from each group were determined by immunohistochemical staining. The representative images are shown. Original magnification was 400×. (C) The protein
expression levels of iNOS and COX-2 in lung tissues from each group were detected by Western blot analysis. Representative bands are shown (left), and the relative
band intensity ratio to endogenous control β-actin was quantified (right). Data are presented as mean ± SD (n = 6). ∗∗p < 0.01 vs. the control group; ##p < 0.01 vs.
the BLM group.
(Figure 6A). The results of real time PCR and Western bolt
analyses also revealed a suppressive effect of iPS cells on TGF-β1
expression in BLM-induced lung fibrosis model (Figures 6B,C).
Furthermore, we also detected the expression of downstream
signaling of TGF-β1, p-Smad2 and p-Smad3 proteins, in the
mouse lung tissues. As shown in Figure 6C, an increased
expression of p-Smad2/3 was observed in BLM-mediated group
when compared to the sham control group. Treatment with
iPS cells to BLM-induced group led to a significant decrease
in the expression of these two proteins. Taken together, these
findings suggest that iPS cells could inhibit BLM-activated
TGF-β1/Smad2/3 signaling pathway in pulmonary fibrosis mice.
iPS Cells Repress BLM-Induced EMT in
Mice
Epithelial to mesenchymal transition, characterized by the
conversion of epithelial cells into mesenchymal cells, is well-
accepted to be a pivotal process during lung fibrosis. In this
work, to further explore the potential role of iPS cells in
pulmonary fibrosis, we also investigated their effects on BLM-
mediated EMT. The results of real time PCR showed that
BLM treatment resulted in a remarkable decrease in the mRNA
expression of epithelial marker E-cadherin, while such reduction
was markedly repressed by iPS cell treatment (Figure 7A).
As presented in Figure 7B, lung tissues from BLM-induced
mice showed less positive cells of E-cadherin staining compared
with those from the sham mice. Of note, this decrease of
E-cadherin expression was partially suppressed by iPS cell
treatment. Western blot analysis confirmed these results observed
in immunofluorescence staining (Figure 7C). By contrast, the
expression levels of mesenchymal markers including fibronectin,
vimentin and α-SMA were strongly up-regulated in BLM-
induced mice and almost down-regulated to the normal levels
in iPS cell-treated mice (Figure 7C). Accordingly, these results
suggest that iPS cells have inhibitory effect on EMT in BLM-
induced pulmonary fibrosis.
iPSC-CM Suppress TGF-β1-Induced
Smad2/3 Signaling and EMT in AECII
In order to understand the detail mechanism of iPS cells
on TGF-β1-Smad signaling and EMT, we treated AECII with
iPSC-CM and/or TGF-β1 and then examined the protein
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FIGURE 6 | Effects of iPS cells on TGF-β1/Smad2/3 signaling pathway in the lung tissues of BLM-mediated mice. (A) The TGF-β1 levels in BALF of each
mouse from control group, BLM-induced group, and BLM+iPS group were examined by ELISA kit. (B) The mRNA expression levels of TGF-β1 in pulmonary tissues
from each group were detected using real time PCR. (C) The protein expression levels of TGF-β1, Smad2/3, and p-Smad2/3 in lung tissues from each group were
analyzed by Western blot. The representative bands are shown (left), and the density values of blots were normalized to the internal control β-actin (right). Data are
expressed as mean ± SD (n = 6). ∗∗p < 0.01 vs. the control group; ##p < 0.01 vs. the BLM group.
expression of smad 2/3 and EMT-associated markers. As
shown in Figure 8A, treatment with iPSC-CM significantly
inhibited the up-regulation of p-Smad2 and p-Smad3 proteins
induced by TGF-β1 in AECII. Moreover, the results of
immunofluorescence staining showed that AECII treated by
TGF-β1 exhibited less positive cells of E-cadherin staining
compared with the control cells, which was confirmed by
Western blot analysis (Figures 8B,C). Additionally, treatment
with TGF-β1 strongly up-regulated the expression levels of
mesenchymal markers including fibronectin, vimentin and
α-SMA in AECII, suggesting induction of EMT by TGF-
β1 (Figure 8C). Nevertheless, it demonstrated that iPSC-CM
treatment remarkably suppressed TGF-β1-induced EMT in
AECII (Figures 8B,C).
DISCUSSION
Pulmonary fibrosis is a progressive fibrotic lung disease with
high morbidity and mortality for which there is no effective
treatment capable of improving or at least suppressing the
progressive course. Accumulating evidence highlights the use
of stem cell-based therapy for this fibrotic lung disease
(Ortiz et al., 2003; Rojas et al., 2005; Ni et al., 2015).
In this study, pulmonary fibrosis was induced in mice by
intratracheal instillation of BLM, and the potential mechanisms
of iPS cells in BLM-induced lung fibrosis were investigated.
The present data indicated that administration of iPS cells
inhibited lung tissue injury caused by BLM, as evidenced by
not only a remarkable reduction in lung W/D weight ratio
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FIGURE 7 | Effects of iPS cells on BLM-mediated EMT in mice with pulmonary fibrosis. (A) The mRNA expression levels of E-cadherin in lung tissues from
each group were determined using real time PCR. (B) Immunofluorescence staining was performed to detect E-cadherin protein expression (red) in lung tissue
sections from each group. Nuclei were visualized by DAPI staining (blue). The representative images of each group are presented. Original magnification was 400×.
(C) The expression levels of EMT-associated proteins in lung tissues from each group were determined using Western blot analysis. The representative bands are
shown (left), and the relative band intensity ratio to β-actin was analyzed (right). Data are expressed as mean ± SD (n = 6). ∗∗p < 0.01 vs. the control group;
##p < 0.01 vs. the BLM group.
and collagen deposition but also an obvious inhibition in
body weight loss. The results further showed that treatment
with iPS cells obviously repressed BLM-induced the release
of inflammatory mediators, including TNF-α, IL-1β, IL-6,
NO and PGE2. The molecular evidence revealed for the
first time that TGF-β1/Smad2/3 signaling pathway and EMT
were suppressed by iPS cell treatment during BLM-mediated
pulmonary fibrosis.
Bleomycin -induced pulmonary fibrosis is the classical
available experiment model for human lung fibrosis and widely
used for investigating the mechanisms of lung injury and
fibrosis (Chen et al., 2013). Growing evidence indicates that
excessive cytokine-mediated inflammation plays a key role in the
initiation of pulmonary fibrosis in the clinical and animal models
(Vasakova et al., 2009; Liu et al., 2012). It has been demonstrated
that BLM induces inflammatory cell infiltration and subsequently
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FIGURE 8 | Effects of iPSC-CM on Smad2/3 signaling and EMT in TGF-β1-induced AECII. The AECII were treated with the collected iPSC-CM (100%) and/or
TGF-β1 (5 ng/ml) for 48 h, whereas the control cells were cultured in the normal iPS medium. (A) The protein expression levels of Smad2/3, and p-Smad2/3 in lung
tissues from each group were analyzed by Western blot. The representative bands are shown (left), and the density values of blots were normalized to the internal
control β-actin (right). (B) Immunofluorescence staining was performed to determine E-cadherin protein expression (red) in AECII from each group. Nuclei were
visualized by DAPI staining (blue). The representative images of each group are presented. Original magnification was 400×. (C) The expression levels of
EMT-associated proteins in AECII from each group were determined using Western blot analysis. The representative bands are shown (left), and the relative band
intensity ratio to β-actin was analyzed (right). Data are expressed as mean ± SD (n = 3). ∗∗p < 0.01 vs. the control group; ##p < 0.01 vs. the TGF-β1-treated group.
Frontiers in Pharmacology | www.frontiersin.org 12 November 2016 | Volume 7 | Article 430
fphar-07-00430 November 11, 2016 Time: 14:42 # 13
Zhou et al. IPSCs Inhibit Pulmonary Fibrosis
FIGURE 9 | The summary of effects of iPS cells on pulmonary fibrosis
in vivo and in vitro as well as the involving mechanisms.
stimulates these cells to secrete pro-inflammatory cytokines,
such as TNF-α, IL-1β, and IL-6 (Scheule et al., 1992), which
was consistent with our data. By contrast, treatment with iPS
cells significantly suppressed such infiltration of inflammatory
cells and release of cytokines, which was in agreement with an
earlier report showing down-regulated effects of iPS cells on
the levels of pro-inflammatory cytokines in BLM-injured lung
tissues (How et al., 2013). Moreover, a number of experimental
studies support the notion that overproduction of NO, resulting
from iNOS over-expression, contributes to the pathogenesis of
BLM-induced pulmonary fibrosis (Galuppo et al., 2010; Di Paola
et al., 2011; Galuppo et al., 2011). The findings of the current
study also demonstrated that BLM led to a marked increase in
NO production and iNOS expression, nevertheless, such increase
was significantly repressed upon iPS cell treatment. Therefore,
these results suggest that the treatment of iPS cells can inhibit
BLM-induced inflammatory responses.
In addition, PGE2, produced from arachidonic acid mainly
by COX-2, has been suggested to be involved in various
inflammatory disorders, and its potential role in lung fibrosis has
been increasingly recognized, however, remains controversial.
Several studies have reported that exogenously supplying
PEG2 protected mice against BLM-induced pulmonary fibrosis
(Wilborn et al., 1995; Failla et al., 2009; Dackor et al., 2011),
whereas some other reports showed the detrimental effects of
PEG2 in BLM-induced fibrotic process (McCann et al., 2011;
Zhao et al., 2014; He et al., 2015). Consistent with the latter
view, we found that PEG2 level and COX-2 expression were
up-regulated after BLM induction. These alterations in lung
tissues were significantly suppressed by treatment with iPS cells.
Our study differed from other studies indicating the benefits
of PEG2 in alleviating pulmonary fibrosis (Failla et al., 2009;
Dackor et al., 2011). We did not directly administrated PEG2
but iPS cells to BLM-treated mice, which thus may be through
affecting upstream pathways of PEG2 not just itself. Additionally,
we measured PEG2 levels and COX-2 expression in lung tissues
on the day 21, the late phase of lung fibrosis, while other studies
either did not assess PEG2 levels or only at early phase such as
7 days after BLM induction. Overall, the results of our present
study provide evidence that the anti-inflammatory effects of
iPS cells on BLM-induced lung fibrosis may be associated with
the down-regulation of COX-2-induced PEG2. However, the
precise mechanisms underlying the regulatory role of iPS cells
in the production of PEG2 induced by BLM need to be further
elucidated.
Recently, TGF-β1 has attracted considerable attention as
a potential therapeutic target for lung fibrosis because of its
cardinal role in initiation and progression of this fibrosis. It
has a potential to activate various pro-inflammatory factors
and mediate inflammatory response (Lei et al., 2011). It also
caused the deposition of type I and type III collagens in
BLM-induced lung fibrosis (Coker et al., 1997). Several studies
have demonstrated that the contribution of TGF-β1 to fibrosis
is mediated mainly through the Smad-dependent signaling
pathway, in which Smad2 and Smad3 are phosphorylated
and then translocated into the nucleus where they induce
the transcription of target genes (Derynck and Zhang, 2003;
Willis and Borok, 2007). Corresponding to previous reports
(Zhao et al., 2010; Liu et al., 2012), we observed that BLM
induced significant increases in TGF-β1 level of BALF and
its expression in lung tissues, whereas transplantation of iPS
cells obviously inhibited BLM-activated TGF-β1. In addition,
iPS cell treatment suppressed BLM-enhanced phosphorylation
of Smad2 and Smad3 in lung tissues. Also, treatment with
iPSC-CM significantly inhibited the up-regulation of p-Smad2
and p-Smad3 in TGF-β1-induced AECII. These observations
suggest that the anti-fibrotic effects of iPS cells on BLM-induced
pulmonary fibrosis may be partly due to the suppression of
TGF-β1/Smad2/3 pathway.
During the progression of pulmonary fibrosis, fibroblasts
and myofibroblasts are considered as the protagonists, which
are mainly derived from alveolar epithelial cells by undergoing
EMT (Chapman, 2011). Our data showed that iPS cell
administration obviously up-regulated E-cadherin expression
and down-regulated the expression of fibronectin, vimentin and
α-SMA in lung tissues of BLM-stimulated mice, suggesting
that iPS cells might suppress pulmonary fibrosis via inhibiting
EMT. Moreover, TGF-β1 plays a predominant role in EMT
process and has been recognized as a primary inducer of EMT
during pulmonary fibrosis (Chen et al., 2014). Previous studies
demonstrated that TGF-β1 could enhance the expression level
of zinc-finger transcriptional factor Snail, which subsequently
suppressed the transcription of E-cadherin (Thiery et al., 2009;
Li et al., 2013). Hence, we speculated that the inhibitory effect of
iPS cells on EMT in BLM-induced mice might be associated with
the suppression of TGF-β1-Smad signaling activation. To test
this speculation, we used Western blot and immunofluorescence
analyses to detect the effect of iPSC-CM on EMT in TGF-
β1-induced AECII, which is commonly used as a model of
pulmonary fibrosis in vitro (Alipio et al., 2011). Consistent
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with the previous studies, we here demonstrated that AECII
treated with TGF-β1 showed obvious EMT, as evidenced by the
decrease of E-cadherin expression and the increase of fibronectin,
vimentin and α-SMA. iPSC-CM treatment significantly repressed
TGF-β1-induced EMT in AECII, supporting our speculation.
Taken together, our findings suggest that the inhibitory effects
of iPS cells on pulmonary fibrosis may partly attribute to the
suppression of TGF-β1-Smad2/3-EMT pathway. However, the
further research is needed.
CONCLUSION
In summary, the present study identified the therapeutic
effects of iPS cells in BLM-induced pulmonary fibrosis mice.
The potential mechanisms involved in such effects of iPS
cells were summarized in Figure 9, which were partially
mediated by the reduction of inflammatory mediators and
inhibition of inflammatory responses in injured lungs. More
importantly, our study provided the first line of evidence
supporting the notion that transplantation of iPS cells could
suppress TGF-β1/Smad2/3 signaling pathway and EMT
during BLM-induced lung fibrosis. These results suggest that
transplantation of iPS cells is a promising therapeutic strategy
for pulmonary fibrosis and provide new insight into its possible
mechanisms.
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